Anzeige
Mehr »
Freitag, 09.01.2026 - Börsentäglich über 12.000 News
Steht diese NASDAQ-Biotech-Aktie jetzt vor einer seltenen Kaufgelegenheit?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CMUG | ISIN: FI4000506811 | Ticker-Symbol: 5NX
Frankfurt
08.01.26 | 08:08
13,850 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
NEXSTIM OYJ Chart 1 Jahr
5-Tage-Chart
NEXSTIM OYJ 5-Tage-Chart
RealtimeGeldBriefZeit
13,45013,85008.01.

Aktuelle News zur NEXSTIM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.12.25Nexstim Receives U.S. Order For Two NBS 6 Therapy Systems-
30.12.25Nexstim Oyj: US Customer Orders Two Nexstim NBS 6 Therapy Systems296Press release, Helsinki, 30 December 2025 at 9 AM (EET) US Customer Orders Two Nexstim NBS 6 Therapy Systems Nexstim Plc ("Nexstim" or "Company") has received an order for two NBS 6 therapy systems...
► Artikel lesen
23.12.25Nexstim Oyj: Inside information: Nexstim Plc Agrees on Next Phase of Exclusivity Agreement with Sinaptica Therapeutics, Inc.92Company Announcement, Helsinki, 23 December 2025 at 9 AM (EET) Inside information: Nexstim Plc Agrees on Next Phase of Exclusivity Agreement with Sinaptica Therapeutics, Inc. Nexstim Plc ("Nexstim"...
► Artikel lesen
16.09.25Nexstim Oyj: Nexstim Receives NBS 5+ System Order from Therapy Customer in United States145Press release, Helsinki, 16 September 2025 at 9 AM (EEST) Nexstim Receives NBS 5+ System Order from Therapy Customer in United States Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an...
► Artikel lesen
15.08.25Nexstim Oyj: Nexstim Plc Half-year Report January 1 - June 30, 2025 (unaudited)154NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 - JUNE 30, 2025 (UNAUDITED) Company announcement, Helsinki, August 15, 2025 at 9 am (EEST) NEXSTIM ACCELERATED GROWTH AND IMPROVED PROFITABILITY IN THE FIRST HALF...
► Artikel lesen
08.08.25Nexstim Oyj: Nexstim Receives NBS System 5 Order from India340Press release, Helsinki, 8 August 2025 at 10 AM (EEST) Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from an Indian distributor. The end customer is a hospital...
► Artikel lesen
30.06.25Nexstim Oyj: Nexstim Plc Signs Exclusivity Agreement with Sinaptica Therapeutics, Inc. as Part of Planned Alzheimer's Collaboration126Company Announcement, Helsinki, 30 June 2025 at 9 AM (EEST) Nexstim Plc Signs Exclusivity Agreement with Sinaptica Therapeutics, Inc. as Part of Planned Alzheimer's Collaboration Nexstim Plc (NXTMH:HEX)...
► Artikel lesen
NEXSTIM Aktie jetzt für 0€ handeln
23.06.25Nexstim Oyj: Nexstim Receives NBS System 5 Order from a University Hospital in Germany225Press release, Helsinki, 23 June 2025 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from a University Hospital in Germany Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order...
► Artikel lesen
05.05.25Nexstim Oyj: Nexstim Plc Business Update Q1 2025289Press release, Helsinki, 5 May 2025, at 9 AM (EEST) Nexstim Plc Business Update Q1 2025 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces the key highlights of the Company's business operations...
► Artikel lesen
27.02.25Nexstim Oyj: Nexstim Plc's Financial Statements Bulletin 2024311Company announcement, Helsinki 27 February 2025 at 9 am (EET) NEXSTIM PLC'S FINANCIAL STATEMENTS BULLETIN 2024 NEXSTIM CONTINUED PROFITABLE GROWTH AND SIGNED SIGNIFICANT PARTNERSHIPS July-December 2024 The...
► Artikel lesen
15.01.25Nexstim Oyj: Insider Information: Nexstim Plc and Sinaptica Therapeutics, Inc. Announce Initiation of Co-Development of the SinaptiStim Precision Neuromodulation System to treat Alzheimer's Disease182 Company Announcement, Helsinki, 15 January 2025 at 9 AM (EET) Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") and Sinaptica Therapeutics, Inc. ("Sinaptica"), a clinical-stage company leading the development...
► Artikel lesen
11 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1